Imagine if you could detect a lung infection just by breathing into a device instead of using uncomfortable swabs. This project creates a way to catch germs from the air you exhale and test them quickly. It's like a high-tech filter that grabs the virus or bacteria so doctors can identify it without invasive procedures.
Current sampling methods for respiratory infections are often invasive or suboptimal, which hinders early detection and increases the economic risk of pandemics.
Two breath-based aerosol sampling devices, AveloCollect and AveloMask, along with associated molecular assays for pathogen detection.
If you are a diagnostic hardware producer dealing with the low patient acceptance of invasive swabs — this project developed AveloCollect and AveloMask devices that provide a non-invasive way to sample exhaled breath aerosols for faster screening.
If you are a government health agency dealing with the trillions of €s in economic losses caused by pandemics — this project developed a scalable sampling method that enables early detection and transmission control at all levels of care.
If you are a testing lab dealing with the need for rapid, multiplex detection of pathogens like influenza or tuberculosis — this project developed a system compatible with lateral-flow assays for immediate results.
Based on available project data, specific pricing or unit costs for the AveloCollect and AveloMask devices are not provided.
Yes, the project specifically aims to develop scalable devices, and the work performed includes a shift to staged production and shipment to align with clinical timelines.
Based on available project data, the specific IP and licensing agreements are not detailed, though the consortium includes two industry partners.
The system is designed to work with molecular assays, viral metagenomics for novel pathogens, and point-of-care lateral-flow assays.
The project period runs from 2024-07-01 to 2028-06-30, suggesting the technology is currently in the development and clinical validation phase.
The consortium is well-balanced for commercialization, featuring a 29% industry ratio with 2 industrial partners and 1 SME. The collaboration spans 5 countries (DE, CH, IT, RO, ZA), combining academic research from 3 universities and 1 research institute with practical industrial production capabilities, as seen in the staged manufacturing of the AveloMask.
Contact Universitätsklinikum Heidelberg
Contact us to explore licensing opportunities for AveloCollect and AveloMask.
